Klinische Studie – Psoriasis und Psoriatische Arthritis (Clinical Trial – Germany)

Zur Studie

with superior selectivity and specificity

Therapeutic peptides

toxins of venomous animals

Derived from evolutionary tuned

which selectively

Peptide drugs

target ion channels

for autoimmune patients

Improving quality of life

Targeting Ion Channels

MORE

si-544 – A Highly Differentiated Asset in Autoimmunity

Best-in-class Kv1.3 blocker
Benchmark for safety and tolerability in autoimmune therapy
Maintains patient’s full immunocompetence
Short treatment course delivers sustained clinical benefit
Pipeline drug for autoimmunity

Our Goal

To improve quality of life for patients by developing best-in-class ion channel blockers.

A highly efficient screening and development platform to identify and optimize the most targeted peptides for our drug development.

News

selectION Announces Initiation of Phase 1b Clinical Trial Evaluating si-544 in Patients with Psoriasis Vulgaris or Psoriatic Arthritis

May 28, 2024

New study follows completion of first-in-human Phase 1b trial in atopic dermatitis patients, in which selectION observed safety and tolerability of si-544 in the treatment of T cell autoimmunity Recruitment is underway, with topline results expected in 4Q24 – San…

Meet selectION, Inc. at the BIO International Convention in San Diego, CA, on June 3^rd to 6^th, 2024

May 20, 2024

SAN DIEGO, May 20, 2024 – Meet selectION’s management team for an update on selectION’s best-in-class ion channel blockers and the status of the clinical work in atopic dermatitis and psoriasis.

Klinische Studie – Psoriasis und Psoriatische Arthritis (Clinical Trial – Germany)

with superior selectivity and specificity

Therapeutic peptides

si-544 – A Highly Differentiated Asset in Autoimmunity

Best-in-class Kv1.3 blocker

Benchmark for safety and tolerability in autoimmune therapy

Maintains patient’s full immunocompetence

Short treatment course delivers sustained clinical benefit

Pipeline drug for autoimmunity

Our Goal

To improve quality of life for patients by developing best-in-class ion channel blockers.

Our Technology

A highly efficient screening and development platform to identify and optimize the most targeted peptides for our drug development.

News & Events

selectION Announces Initiation of Phase 1b Clinical Trial Evaluating si-544 in Patients with Psoriasis Vulgaris or Psoriatic Arthritis

Meet selectION, Inc. at the BIO International Convention in San Diego, CA, on June 3^rd to 6^th, 2024

About

Recent News

Contact

Klinische Studie – Psoriasis und Psoriatische Arthritis (Clinical Trial – Germany)

with superior selectivity and specificity

Therapeutic peptides

si-544 – A Highly Differentiated Asset in Autoimmunity

Best-in-class Kv1.3 blocker

Benchmark for safety and tolerability in autoimmune therapy

Maintains patient’s full immunocompetence

Short treatment course delivers sustained clinical benefit

Pipeline drug for autoimmunity

Our Goal

To improve quality of life for patients by developing best-in-class ion channel blockers.

Our Technology

A highly efficient screening and development platform to identify and optimize the most targeted peptides for our drug development.

News & Events

selectION Announces Initiation of Phase 1b Clinical Trial Evaluating si-544 in Patients with Psoriasis Vulgaris or Psoriatic Arthritis

Meet selectION, Inc. at the BIO International Convention in San Diego, CA, on June 3rd to 6th, 2024

About

Recent News

Contact

Meet selectION, Inc. at the BIO International Convention in San Diego, CA, on June 3^rd to 6^th, 2024